PMID- 8739540
OWN - NLM
STAT- MEDLINE
DCOM- 19961009
LR  - 20071115
IS  - 0392-9590 (Print)
IS  - 0392-9590 (Linking)
VI  - 15
IP  - 1
DP  - 1996 Mar
TI  - Low molecular weight heparins in the initial treatment of deep vein thrombosis.
PG  - 67-74
AB  - All major trials to-date provide strong evidence that, for the initial treatment 
      of DVT, adjusted-dose LMWHs are at least as effective and safe as unfractionated 
      heparin (UFH). When compared with UFH, LMWHs achieved better thrombus lysis and 
      had less bleeding complications (21-91% risk reduction) and mortality (51% 
      reduction). They also reduced the incidence of recurrent DVT and PE at 90 days 
      follow-up while there was no need for monitoring. Despite these exciting findings 
      however, long-term evaluation of mortality rate, recurrent venous 
      thromboembolism, blood monitoring tests efficacy and thrombus 
      propagation/reduction are open issues. Furthermore, venous haemodynamics have 
      never been tested. There is an ongoing Canadian study today, aiming to determine 
      LMWHs effectiveness in reducing death, recurrent venous thromboembolism and 
      haemorrhagic complications; it is obvious however that further studies are 
      needed. We must determine if a prolonged use of LMWHs (i.e. 90 days) is more 
      effective in preventing the post-thrombotic sequelae, reducing also the incidence 
      of haemorrhagic complications; we also need to know the nature of the 
      haematological changes that develop and the relationship between these changes 
      and the recurrence rate; and finally, we must identify effective blood tests to 
      monitor this treatment.
FAU - Volteas, S K
AU  - Volteas SK
AD  - Academic Vascular Unit, St. Mary's Hospital Medical School, London, UK.
FAU - Kalodiki, E
AU  - Kalodiki E
FAU - Nicolaides, A N
AU  - Nicolaides AN
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Int Angiol
JT  - International angiology : a journal of the International Union of Angiology
JID - 8402693
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Heparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Recurrence
MH  - Thrombophlebitis/*drug therapy
MH  - Time Factors
RF  - 46
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
PST - ppublish
SO  - Int Angiol. 1996 Mar;15(1):67-74.